Abstract:AIMS: Interleukin (IL)-22 activates multiple signaling pathways to exert anti-inflammatory effects, but few studies have examined whether and how IL-22 may shift macrophage polarization between M1 (pro-inflammatory) and M2 (anti-inflammatory) states and thereby influence the progression of hepatic fibrosis.MAIN METHODS: Utilized CCl4 to induce liver fibrosis in mice, detected the role of IL-22 in inhibiting liver fibrosis by regulating Kupffer cells (KCs) polarization in vivo and in vitro. U937 cells were used to confirm the mechanism of IL-22 regulating macrophage polarization via the STAT3/Erk/Akt pathways. Human liver specimens were collected to verify the correlation between the levels of IL-22 and KCs during liver fibrogenesis.KEY FINDINGS: During CCl4-induced liver fibrosis progression in mice, adding exogenous IL-22 significantly inhibited pro-fibrogenic and macrophage phenotype-altering factors secreted by M1-KCs, and it increased the number of M2-KCs. In co-cultures of hepatic stellate cells and KCs from mice treated with IL-22, a high M2/M1-KCs ratio inhibited collagen production and stellate cell activation. These results suggest that IL-22 can increase the ratio of M2-KCs to M1-KCs and thereby attenuate the progression of liver fibrosis. Mechanistic studies in vitro showed that IL-22 promoted polarization of lipopolysaccharide-treated U937 macrophages from M1 to M2. The cytokine exerted these effects by activating the STAT3 pathway while suppressing Erk1/2 and Akt pathways. Furthermore, immunofluorescent staining in human liver specimens confirmed that IL-22 levels positively correlated with the number of M2-KCs during liver fibrogenesis.SIGNIFICANCE: IL-22 regulates the STAT3/Erk/Akt to increase the M2/M1-KCs ratio and thereby slow liver fibrogenesis.

What problem does this paper attempt to address?

The problem this paper attempts to address is whether interleukin-22 (IL-22) can alleviate the progression of liver fibrosis by regulating the polarization state of Kupffer cells (KCs). Specifically, the researchers explored how IL-22 influences the transition of KCs from pro-inflammatory M1 type to anti-inflammatory M2 type through the interaction of the STAT3/Erk/Akt signaling pathways, thereby inhibiting the progression of liver fibrosis. ### Background and Problem 1. **Background of Liver Fibrosis**: - Liver fibrosis is the liver's intrinsic response to chronic injury, with common causes including hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. - Persistent fibrosis caused by chronic HBV infection can form scar tissue, eventually leading to cirrhosis, increasing mortality and morbidity. 2. **Limitations of Existing Treatments**: - Anti-fibrotic treatments typically involve inhibiting epithelial-mesenchymal transition, reducing intrahepatic inflammation, promoting hepatocyte regeneration, and promoting the secretion of matrix metalloproteinases. - Although existing treatments are effective, they do not comprehensively cover all pathways of liver fibrosis occurrence and progression, necessitating the search for more effective treatments. 3. **Role of Kupffer Cells**: - Kupffer cells are resident macrophages in the liver that are first activated upon contact with bacteria, bacterial endotoxins, and intestinal debris. - Kupffer cells play a crucial role in tissue repair after liver injury or infection but may also promote the progression of liver diseases, including hepatitis, fibrosis, and cancer. - Kupffer cells can differentiate into pro-inflammatory M1 type or anti-inflammatory M2 type, and the regulation of their polarization state significantly impacts the progression of liver fibrosis. 4. **Role of IL-22**: - Preliminary studies suggest that IL-22 can inhibit the secretion of pro-inflammatory factors by M1 macrophages induced by lipopolysaccharide (LPS). - IL-22 protects the liver from acute and chronic alcoholic injury by binding to the IL-22R1 and IL-10R2 receptor complex on the surface of hepatocytes. - IL-22 can also induce senescence in hepatic stellate cells (HSCs), thereby alleviating liver fibrosis. ### Research Objectives - To investigate whether IL-22 can inhibit the progression of liver fibrosis by regulating the polarization state of Kupffer cells. - To study the specific mechanisms by which IL-22 influences the transition of Kupffer cells from M1 type to M2 type through the interaction of the STAT3/Erk/Akt signaling pathways. ### Main Methods - **Animal Model**: Using a CCl4-induced mouse model of liver fibrosis to detect the effects of IL-22 on Kupffer cell polarization in vivo and in vitro. - **Cell Experiments**: Utilizing U937 cells to verify the mechanism by which IL-22 regulates macrophage polarization through the STAT3/Erk/Akt signaling pathways. - **Clinical Samples**: Collecting human liver tissue samples to verify the correlation between IL-22 levels and the number of Kupffer cells during the process of liver fibrosis. ### Key Findings - In the CCl4-induced mouse model of liver fibrosis, exogenous IL-22 significantly inhibited the secretion of pro-fibrotic and phenotypic change factors by M1 type Kupffer cells and increased the number of M2 type Kupffer cells. - In co-cultured hepatic stellate cells and Kupffer cells, a high M2/M1 ratio inhibited collagen production and stellate cell activation. - In vitro experiments showed that IL-22 promoted the transition of LPS-treated U937 macrophages from M1 type to M2 type, an effect achieved by activating the STAT3 pathway and inhibiting the Erk1/2 and Akt pathways. - Immunofluorescence staining confirmed that IL-22 levels in human liver tissue were positively correlated with the number of M2 type Kupffer cells. ### Significance - IL-22 alleviates the progression of liver fibrosis by regulating the STAT3/Erk/Akt signaling pathways, increasing the M2/M1 ratio of Kupffer cells. - This finding provides a theoretical basis for developing new anti-fibrotic treatments.

Interleukin-22 regulating Kupffer cell polarization through STAT3/Erk/Akt crosstalk pathways to extenuate liver fibrosis

Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice

Amelioration of High Fat Diet Induced Liver Lipogenesis and Hepatic Steatosis by Interleukin-22.

422.9: ILC2s Regulate Kupffer Cells Polarization to Alleviate Hepatic Ischemia-Reperfusion Injury Via IL-4/JNK/STAT3 Pathway

In Vivo Consequences of Liver-Specific Interleukin-22 Expression in Mice: Implications for Human Liver Disease Progression

IL-8 exacerbates CCl4-induced liver fibrosis in human IL-8-expressing mice via the PI3K/Akt/HIF-1α pathway

Roles of Kupffer Cell Polarization and Hepatic Stellate Cell Activation in Hepatic Inflammation and Fibrosis in NAFLD

Profibrogenic role of IL-15 through IL-15 receptor alpha-mediated trans-presentation in the carbon tetrachloride-induced liver fibrosis model

Pathological Functions of Interleukin-22 in Chronic Liver Inflammation and Fibrosis with Hepatitis B Virus Infection by Promoting T Helper 17 Cell Recruitment

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2

Increased IL-22-producing cells contribute to liver fibrosis through promoting Th17 migration in chronic HBV patients (P3363)

Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets

Down-regulation of IL-25 Accompanied by a Decrease in the Number of M2 Macrophages in Patients of Non-Alcoholic Fatty Liver Disease with Significant Liver Fibrosis

Clonorchis Sinensis Lysophospholipase A Upregulates Il-25 Expression in Macrophages As A Potential Pathway to Liver Fibrosis

The Role of Interleukin-22 in Liver Regeneration after Partial Hepatectomy with Liver Fibrosis in Mice

Immune Regulation of Intrahepatic Regulatory T Cells in Fibrotic Livers of Mice.

Interleukin-22 alleviates alcohol-associated hepatic fibrosis, inhibits autophagy, and suppresses the PI3K/AKT/mTOR pathway in mice

Exploring the Potential of Treating Chronic Liver Disease Targeting the PI3K/Akt Pathway and Polarization Mechanism of Macrophages

Activated Hepatic Stellate Cells Induce Infiltration and Formation of CD163+ Macrophages via CCL2/CCR2 Pathway

IDDF2024-ABS-0230 CCL2-CCR2 Axis Inhibition Reduces Liver Fibrosis by Restoring the Immune Cell Landscape

Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells